PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 12031601

Decrease of serum dipeptidylpeptidase activity in severe sepsis patients: relationship to procalcitonin.

Andreas Bergmann·Claude Bohuon
View original source ↗Export metadata ↓

Abstract

A significant decrease of DPP IV activity has been found in patients with severe sepsis in relationship to the increase of procalcitonin. These findings might be explained by the high concentration of other substrates for DPP IV present in these patients. It can be hypothesized that this enzymatic decrease is bound to some changes in immunomodulation. Further studies will be necessary to elucidate the clinical importance of these findings.

Explore related subjects

CalcitoninCalcitonin Gene-Related PeptideDipeptidyl Peptidase 4FluorometryHumansProtein PrecursorsSepsisStatistics as TopicJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Andreas Bergmann, Claude Bohuon. 2002. Decrease of serum dipeptidylpeptidase activity in severe sepsis patients: relationship to procalcitonin.. https://doi.org/10.1016/s0009-8981(02)00042-6

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2004

Direct determination of the peptide content in microspheres by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

A quantitative determination of peptides incorporated into poly(d,l-lactide-co-glycolide) microspheres by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) was accomplished in a single step without pretreatment for extracting the peptide from the microsphere. The conventional extraction methods often underestimate the actual amount of peptide because of incomplete extraction from the microspheres or loss during the procedures. In this study, the microspheres dissolved in acetonitrile containing 0.1% trifluoroacetic acid were mixed with matrix solution containing the internal standard, and the peptide content was directly determined by MALDI-TOF MS. The drug content values determined by MALDI-TOF MS in both the leuprolide- and salmon calcitonin-incorporated microspheres were closer to the theoretical contents than those determined by the conventional extraction method. This method using MALDI-TOF MS could be a good alternative to time-consuming and less-accurate conventional methods.

Calcitonin↗
PubMed2004

The cholecystokinin2-receptor mediates calcitonin secretion, gene expression, and proliferation in the human medullary thyroid carcinoma cell line, TT.

Gastrin-induced release of calcitonin from medullary thyroid carcinomas (MTC) is based on the expression of the cholecystokinin(2)-receptor (CCK(2)R) in these tumors. Recently, we have shown that the CCK(2)R is expressed not only in MTC but also in C-cells within the normal thyroid gland. The functions of the CCK(2)R in MTC and C-cells are largely unknown. We therefore explored the effects of gastrin-induced CCK(2)R stimulation in the highly differentiated MTC cell line, TT. CCK(2)R expression in TT-cells is detectable by RT-PCR as well as immunocytochemistry. Stimulation of the CCK(2)R by gastrin induces immediate release of calcitonin from TT-cells. Moreover, quantitative (LightCycler) RT-PCR demonstrates that gastrin stimulates transcription of the calcitonin and chromogranin A genes in TT-cells. TT-cell proliferation, assessed by counting of viable cells and (3)H-thymidine uptake, is markedly increased by gastrin. This effect is inhibited by the CCK(2)R-specific antagonist L-365,260. Our findings suggest physiological functions for the CCK(2)R in calcitonin-secretion and gene expression as well as a pathophysiological role in MTC proliferation. CCK(2)R antagonists might have therapeutic potential in these tumors.

Calcitonin↗